PE20140337A1 - Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico - Google Patents
Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-aceticoInfo
- Publication number
- PE20140337A1 PE20140337A1 PE2013000799A PE2013000799A PE20140337A1 PE 20140337 A1 PE20140337 A1 PE 20140337A1 PE 2013000799 A PE2013000799 A PE 2013000799A PE 2013000799 A PE2013000799 A PE 2013000799A PE 20140337 A1 PE20140337 A1 PE 20140337A1
- Authority
- PE
- Peru
- Prior art keywords
- pyridin
- trifluoro
- phenyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
SE REFIERE A FORMAS CRISTALINAS DE LA SAL SODICA DEL ACIDO (4-{4-[5-(6-TRIFLUORO-METIL-PIRIDIN-3-IL-AMINO)-PIRIDIN-2-IL]-FENIL}-CICLOHEXIL)-ACETICO, EN LA FORMA DE MODIFICACION B, C, D, N, ENTRE OTRAS. EN LA MODIFICACION C SE CARACTERIZA POR TENER UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X QUE COMPRENDE CUATRO O MAS VALORES 2?( �0.1grado) (CuK ? ? = 1.5418�) SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN 5.9, 17.0, 19.6, ENTRE OTROS; EN LA MODIFICACION N SE CARACTERIZA POR TENER UN PATRON DE DIFRACCION EN POLVO DE RAYOS-X QUE COMPRENDE CUATRO O MAS VALORES 2?( �0.1grado) (CuK ? ? = 1.5418�) SELECCIONADOS A PARTIR DEL GRUPO QUE CONSISTE EN 6.2, 3.3, 16.6, ENTRE OTROS; TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y ES UTIL EN EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACTIVIDAD DEL DGAT1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39088810P | 2010-10-07 | 2010-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20140337A1 true PE20140337A1 (es) | 2014-03-13 |
Family
ID=44802409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2013000799A PE20140337A1 (es) | 2010-10-07 | 2011-10-05 | Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico |
Country Status (25)
Country | Link |
---|---|
US (2) | US8829194B2 (es) |
EP (2) | EP2781516B1 (es) |
JP (1) | JP6093703B2 (es) |
KR (2) | KR101900652B1 (es) |
CN (1) | CN103153981B (es) |
AR (1) | AR083317A1 (es) |
AU (1) | AU2011312185B2 (es) |
BR (1) | BR112013008355A2 (es) |
CA (1) | CA2813736C (es) |
CL (1) | CL2013000929A1 (es) |
CO (1) | CO6710909A2 (es) |
EC (1) | ECSP13012608A (es) |
ES (2) | ES2618411T3 (es) |
GT (1) | GT201300089A (es) |
IL (1) | IL225532A0 (es) |
MA (1) | MA34645B1 (es) |
MX (1) | MX2013003835A (es) |
NZ (1) | NZ608557A (es) |
PE (1) | PE20140337A1 (es) |
PL (2) | PL2625172T3 (es) |
PT (2) | PT2781516T (es) |
RU (1) | RU2612556C2 (es) |
SG (1) | SG188586A1 (es) |
TW (1) | TW201217360A (es) |
WO (1) | WO2012047948A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101900652B1 (ko) * | 2010-10-07 | 2018-09-19 | 노파르티스 아게 | (4-{4-[5-(6-트리플루오로메틸-피리딘-3-일아미노)-피리딘-2-일]-페닐}-시클로헥실)-아세트산의 나트륨 염의 신규 결정형 |
CA2844835A1 (en) * | 2011-09-12 | 2013-03-21 | Uwe Grether | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides |
MX357768B (es) * | 2012-04-27 | 2018-07-24 | Novartis Ag | Inhibidores de dgat1 de eter ciclico de cabeza de puente. |
WO2013163508A1 (en) * | 2012-04-27 | 2013-10-31 | Novartis Ag | Tetrahydropyran dgat1 inhibitors |
WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
KR101646716B1 (ko) | 2016-02-15 | 2016-08-08 | 서성환 | 조립식 나선계단용 스페이서 및 이를 이용한 조립식 나선계단 |
MX2021007544A (es) * | 2018-12-20 | 2021-08-11 | Merck Sharp & Dohme Llc | Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
PE20050157A1 (es) | 2003-05-20 | 2005-05-17 | Novartis Ag | Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar) |
US20050226906A1 (en) | 2004-04-08 | 2005-10-13 | Micro Nutrient, Llc | Nutrient system for individualized responsive dosing regimens |
CA2647819C (en) * | 2006-03-31 | 2012-12-11 | Novartis Ag | Phenylcyclohexyl derivatives as dgat1 inhibitors |
CA2671315A1 (en) * | 2006-12-11 | 2008-06-19 | Novartis Ag | Method of preventing or treating myocardial ischemia by inhibiting dgat1 enzyme with a dgat1 inhibitor |
KR101900652B1 (ko) * | 2010-10-07 | 2018-09-19 | 노파르티스 아게 | (4-{4-[5-(6-트리플루오로메틸-피리딘-3-일아미노)-피리딘-2-일]-페닐}-시클로헥실)-아세트산의 나트륨 염의 신규 결정형 |
-
2011
- 2011-10-05 KR KR1020187001729A patent/KR101900652B1/ko active IP Right Grant
- 2011-10-05 PT PT131977142T patent/PT2781516T/pt unknown
- 2011-10-05 PT PT117706226T patent/PT2625172T/pt unknown
- 2011-10-05 ES ES11770622.6T patent/ES2618411T3/es active Active
- 2011-10-05 ES ES13197714.2T patent/ES2618426T3/es active Active
- 2011-10-05 NZ NZ608557A patent/NZ608557A/en not_active IP Right Cessation
- 2011-10-05 WO PCT/US2011/054841 patent/WO2012047948A1/en active Application Filing
- 2011-10-05 PE PE2013000799A patent/PE20140337A1/es not_active Application Discontinuation
- 2011-10-05 AR ARP110103699A patent/AR083317A1/es unknown
- 2011-10-05 CN CN201180048559.6A patent/CN103153981B/zh active Active
- 2011-10-05 PL PL11770622T patent/PL2625172T3/pl unknown
- 2011-10-05 BR BR112013008355A patent/BR112013008355A2/pt not_active IP Right Cessation
- 2011-10-05 CA CA2813736A patent/CA2813736C/en active Active
- 2011-10-05 EP EP13197714.2A patent/EP2781516B1/en active Active
- 2011-10-05 RU RU2013120549A patent/RU2612556C2/ru active
- 2011-10-05 AU AU2011312185A patent/AU2011312185B2/en active Active
- 2011-10-05 MX MX2013003835A patent/MX2013003835A/es active IP Right Grant
- 2011-10-05 US US13/876,063 patent/US8829194B2/en active Active
- 2011-10-05 JP JP2013532893A patent/JP6093703B2/ja active Active
- 2011-10-05 SG SG2013019906A patent/SG188586A1/en unknown
- 2011-10-05 PL PL13197714T patent/PL2781516T3/pl unknown
- 2011-10-05 KR KR1020137011696A patent/KR20130115277A/ko not_active Application Discontinuation
- 2011-10-05 EP EP11770622.6A patent/EP2625172B1/en active Active
- 2011-10-06 TW TW100136327A patent/TW201217360A/zh unknown
-
2013
- 2013-04-02 IL IL225532A patent/IL225532A0/en unknown
- 2013-04-04 GT GT201300089A patent/GT201300089A/es unknown
- 2013-04-05 CL CL2013000929A patent/CL2013000929A1/es unknown
- 2013-04-08 CO CO13090547A patent/CO6710909A2/es unknown
- 2013-05-03 MA MA35870A patent/MA34645B1/fr unknown
- 2013-05-07 EC ECSP13012608 patent/ECSP13012608A/es unknown
-
2014
- 2014-07-31 US US14/448,011 patent/US20140343102A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20140337A1 (es) | Nuevas formas cristalinas de la sal sodica del acido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclhexil)-acetico | |
EA201201648A1 (ru) | Стимуляторы sgc | |
MX2015018048A (es) | Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos. | |
PE20100260A1 (es) | Formas solidas del (2s, 3r, 4r, 5s, 6r)-2-(4-cloro-3-(4-etoxibenzil)fenil)-6-(metiltio) tetrahidro-2h-pirano-3,4,5-triol | |
EA201890641A2 (ru) | СТИМУЛЯТОРЫ sGC | |
PE20120989A1 (es) | Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo | |
CR20140057A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos | |
MX366393B (es) | Sales o co-cristales de 3-(3-dimetilamino-1-etil-2-metil-propil)-f enol. | |
AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
PE20140978A1 (es) | Composicion farmaceutica solida que contiene amlodipina y losartan y el proceso para producirla | |
PE20140389A1 (es) | Composiciones y metodos para el tratamiento de la mielofibrosis | |
AR087451A1 (es) | Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes | |
CL2013000756A1 (es) | Forma cristalaina del citrato diacido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano; proceso de preparacion; composicion farmaceutica; y su uso para tratar o prevenir un trastorno de la memoria, un trastorno cognitivo, neurodegeneracion, entre otros. | |
EA201591618A1 (ru) | Замещенные имидазопиридазины | |
AR102915A1 (es) | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable | |
RU2016124158A (ru) | Композиция для ухода за полостью рта, содержащая серин и по меньшей мере соль цинка | |
AR109729A1 (es) | Método para producir la forma cristalina de modificación a de calcobutrol | |
PE20142399A1 (es) | Compuestos de pirazol como inhibidores de sglt1 | |
CL2011002045A1 (es) | Compuesto derivado de n-[(3e)-5-(cicloalquilamino)-5-oxo-1-fenilpent-3-en-2-il]benzamida, utiles en el tratamiento del prurito de causa desconocido o asociado a una enfermedad dermatologica tal como dermatitis atopica, psoriasis, urticaria, entre otras; combinacion farmaceutica. | |
EA201171289A1 (ru) | Композиция для укладки волос | |
CL2015000957A1 (es) | Métodos para reducir la formación de encrustante | |
PE20100085A1 (es) | Formas solidas de (1r,2s,3r)-1-(2-(isoxazol-3-il)-1h-imidazol-4-il)butano-1,2,3,4-tetraol y metodos de uso | |
AR083166A1 (es) | Derivados de alquil-piperazin-fenil 4(3h)-quinazolinonas utiles para tratar depresion, ansiedad, disfunciones sexuales femeninas y otras patologias del sistema nervioso central, y composiciones farmaceuticas que los contienen | |
HRP20201533T1 (hr) | Preparat za liječenje artritisa i artroze | |
PE20110559A1 (es) | (4bR,6R,7R,8aS)-4b-BENCIL-6,7-DIHIDROXI-6-METIL-N-(2-METILPIRIDIN-3-IL)-10-OXO-7-FENIL-4b,5,6,7,8,8a,9,10-OCTAHIDROFENANTRENO-2-CARBOXAMIDA COMO MODULADOR DEL RECEPTOR GLUCOCORTICOIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |